Reimbursement
and Support for Dermacyte Matrix
Merakris offers a comprehensive reimbursement support for providers using Dermacyte Matrix. To start the insurance verification process, use this form:
Dermacyte Amniotic Wound Care Matrix
Harnessing the power of amniotic tissue to advance wound healing
The Dermacyte Difference: Real-World Evidence in Wound Care1
Dermacyte Matrix represents an innovative approach in advanced wound care.
DERMACYTE MATRIX is a commercially available extracellular tissue product and is intended for use as a protective covering for partial and full thickness wounds and surgical sites.
Dermacyte® Matrix
Dermacyte® Amniotic Wound Care Matrix (Dermacyte Matrix) is a human amniotic membrane allograft with a preserved epithelial basement membrane and compact fibroblast layer.
Based on proprietary advancements in amniotic tissue processing, Dermacyte Matrix is created from amniotic tissue that undergoes rigorous screening and is produced under the highest quality standards.
Dermacyte Matrix excels in 
Convenience:
Ease of use across various clinical settings.
Clinically Tested:
Peer reviewed literature in multiple applications.1
Protection:
Wound bed protection from the external environment.
Storage Efficiency:
Stable and uncomplicated storage
Application and Usage of Dermacyte Matrix
Dermacyte Matrix provides a protective barrier to cover wounds and soft tissue.
Dermacyte Matrix is a versatile covering that may be applied to various hard-to-heal wounds, including:
Diabetic ulcers
Venous ulcers
Pressure ulcers
Burns
Deep dermal ulcers exposing underlying tendons, muscles or bones
Dermacyte Matrix Specifications
| Product SKU | Identifier | Matrix Size (LxW, cm) |
| AM-D10012 | MT10012 | 1×2 |
| AM-D10022 | MT10022 | 2×2 |
| AM-D10023 | MT10023 | 2×3 |
| AM-D10024 | MT10024 | 2×4 |
| AM-D10044 | MT10044 | 4×4 |
| AM-D10046 | MT10046 | 4×6 |
| AM-D10048 | MT10048 | 4×8 |
| AM-D10912 | MT10912 | 9×12 |
Reimbursement
Dermacyte Matrix is regulated by the U.S. Food and Drug Administration (FDA) as a minimally manipulated human allograft tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1271.
Regulatory Compliance
Merakris Therapeutics is committed to being a best in class organization in the development and commercialization of healthcare technologies in order to provide customers the highest quality products that offer consistent safety and performance.
FDA registered and audited source facilities
Manufactured in accordance with 21 CFR 1271
References:
- Ditmars FS, Kay KE, Broderick TC, Fagg WS. Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study. J Wound Care. 2024 Mar 1;33(Sup3):S44-S50. doi: 10.12968/jowc.2024.33.Sup3.S44. PMID: 38457299.
Partner with us for advanced wound care
Interested in learning more about using or distributing Dermacyte Matrix?